Portfolio Holdings Detail for ISIN IE0009VWHAE6
| Stock Name / Fund | iShares US Equity Enhanced Active UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares III Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300PZLRJB7M8H1057 |
| ETF Ticker | USEE(USD) Euronext Amsterdam |
Holdings detail for BPMC
| Stock Name | Blueprint Medicines Corp |
| Ticker | BPMC(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US09627Y1091 |
| LEI | 5299004CC60O9T5HVM83 |
Show aggregate BPMC holdings
News associated with BPMC
- US Bancorp DE Sells 1,657 Shares of Blueprint Medicines Corporation (NASDAQ:BPMC)
- US Bancorp DE decreased its position in shares of Blueprint Medicines Corporation (NASDAQ:BPMC – Free Report) by 16.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,326 shares of the biotechnology company’s stock after selling 1,657 shares during the quarter. US Bancorp DE’s […] - 2025-08-11 05:14:59
- Blueprint Medicines Corporation (NASDAQ:BPMC) Shares Sold by XTX Topco Ltd
- XTX Topco Ltd lessened its stake in shares of Blueprint Medicines Corporation (NASDAQ:BPMC – Free Report) by 34.4% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,311 shares of the biotechnology company’s stock after selling 3,835 shares during the […] - 2025-08-06 05:17:00
- KLP Kapitalforvaltning AS Trims Stake in Blueprint Medicines Corporation (NASDAQ:BPMC)
- KLP Kapitalforvaltning AS lowered its position in Blueprint Medicines Corporation (NASDAQ:BPMC – Free Report) by 4.7% in the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 12,300 shares of the biotechnology company’s stock after selling 600 shares during the period. KLP Kapitalforvaltning AS’s holdings in Blueprint Medicines […] - 2025-07-29 06:16:52
- Blueprint Medicines Corporation (NASDAQ:BPMC) Shares Acquired by Cwm LLC
- Cwm LLC raised its stake in shares of Blueprint Medicines Corporation (NASDAQ:BPMC – Free Report) by 62.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,321 shares of the biotechnology company’s stock after acquiring an additional 2,042 shares during the quarter. Cwm LLC’s […] - 2025-07-25 05:03:11
- Wall Street Zen Upgrades Blueprint Medicines (NASDAQ:BPMC) to Hold
- Wall Street Zen upgraded shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) to a hold rating in a report released on Friday. Several other equities analysts have also recently commented on the stock. Wells Fargo & Company cut shares of Blueprint Medicines from a “strong-buy” rating to a “hold” rating and reduced their price objective […] - 2025-07-21 04:58:55
- Blueprint Medicines Corporation (NASDAQ:BPMC) Stock Position Raised by Xponance Inc.
- Xponance Inc. raised its position in shares of Blueprint Medicines Corporation (NASDAQ:BPMC – Free Report) by 5.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,021 shares of the biotechnology company’s stock after purchasing an additional 240 shares during the period. […] - 2025-07-18 05:01:08
- After Hours Most Active for Jul 16, 2025 : SRPT, NVDA, AAPL, BPMC, PFE, QQQ, INTC, CNH, GE, NI, WFC, F
- The NASDAQ 100 After Hours Indicator is down -7.97 to 22,900. The total After hours volume is currently 113,085,350 shares traded.The following are the most active stocks for the after hours session: Sarepta Therapeutics, Inc. (SRPT) is +6.94 at $25.32, with 4,918,743 shares tra - 2025-07-16 17:24:53
- Calamos Advisors LLC Purchases New Shares in Blueprint Medicines Corporation (NASDAQ:BPMC)
- Calamos Advisors LLC bought a new stake in Blueprint Medicines Corporation (NASDAQ:BPMC – Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 3,721 shares of the biotechnology company’s stock, valued at approximately $329,000. Several other institutional investors have also modified […] - 2025-07-08 05:46:52
- Exchange Traded Concepts LLC Sells 626 Shares of Blueprint Medicines Corporation (NASDAQ:BPMC)
- Exchange Traded Concepts LLC reduced its position in Blueprint Medicines Corporation (NASDAQ:BPMC – Free Report) by 31.2% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 1,383 shares of the biotechnology company’s stock after selling 626 shares during the period. Exchange Traded Concepts LLC’s holdings in Blueprint Medicines […] - 2025-06-24 04:36:54
- Wells Fargo & Company Downgrades Blueprint Medicines (NASDAQ:BPMC) to Hold
- Blueprint Medicines (NASDAQ:BPMC – Get Free Report) was downgraded by Wells Fargo & Company from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Tuesday, MarketBeat Ratings reports. They presently have a $129.00 target price on the biotechnology company’s stock, down from their prior target price of $143.00. Wells […] - 2025-06-19 02:42:48
- NBC Securities Inc. Purchases 2,646 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)
- NBC Securities Inc. lifted its stake in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 132,300.0% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,648 shares of the biotechnology company’s stock after purchasing an additional 2,646 shares during the […] - 2025-06-08 05:46:56
- TD Cowen Downgrades Blueprint Medicines (NASDAQ:BPMC) to Hold
- TD Cowen cut shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) from a strong-buy rating to a hold rating in a research note issued to investors on Tuesday morning,Zacks.com reports. Several other brokerages have also issued reports on BPMC. Needham & Company LLC lowered shares of Blueprint Medicines from a “moderate buy” rating to a […] - 2025-06-06 02:58:54
- Blueprint Medicines (NASDAQ:BPMC) Cut to Hold at Citizens Jmp
- Citizens Jmp downgraded shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) from a strong-buy rating to a hold rating in a report issued on Tuesday,Zacks.com reports. Several other brokerages have also issued reports on BPMC. Wedbush reissued a “neutral” rating and issued a $129.00 price target (up previously from $128.00) on shares of Blueprint Medicines […] - 2025-06-06 02:58:54
- Blueprint Medicines (NASDAQ:BPMC) Stock Rating Lowered by Needham & Company LLC
- Blueprint Medicines (NASDAQ:BPMC – Get Free Report) was downgraded by research analysts at Needham & Company LLC from a “moderate buy” rating to a “hold” rating in a research note issued on Monday, MarketBeat Ratings reports. They presently have a $130.00 price objective on the biotechnology company’s stock. Needham & Company LLC’s price target indicates […] - 2025-06-04 02:34:54
- Scotiabank Reiterates Sector Perform Rating for Blueprint Medicines (NASDAQ:BPMC)
- Scotiabank reiterated their sector perform rating on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a report released on Monday morning,Benzinga reports. They currently have a $135.00 price objective on the biotechnology company’s stock. Several other equities analysts have also recently issued reports on BPMC. Needham & Company LLC reiterated a “hold” rating and […] - 2025-06-03 02:52:45
- Sanofi To Acquire Blueprint Medicines In $9.5 Bln Deal
- (RTTNews) - Sanofi (SNYNF, SNY) announced Monday that it has agreed to acquire Blueprint Medicines Corp. (BPMC) in a transaction valued at about $9.5 billion on a fully diluted basis, including potential contingent value right payments. - 2025-06-02 02:29:00
- Analysts See 14% Upside For IYY
- Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-05-27 10:00:48
- Blueprint Medicines Co. (NASDAQ:BPMC) Stock Position Boosted by Nuveen Asset Management LLC
- Nuveen Asset Management LLC increased its stake in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 49.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 419,190 shares of the biotechnology company’s stock after acquiring an additional 138,176 shares during the […] - 2025-05-21 06:30:49
- Captrust Financial Advisors Trims Stake in Blueprint Medicines Co. (NASDAQ:BPMC)
- Captrust Financial Advisors reduced its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 53.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,331 shares of the biotechnology company’s stock after selling 9,573 shares during the period. Captrust […] - 2025-05-18 05:49:11
- Ameriprise Financial Inc. Has $29.49 Million Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)
- Ameriprise Financial Inc. raised its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 4.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 338,115 shares of the biotechnology company’s stock after acquiring an additional 13,501 shares during the period. Ameriprise Financial Inc.’s holdings […] - 2025-05-14 05:41:05
- Dimensional Fund Advisors LP Has $3.51 Million Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)
- Dimensional Fund Advisors LP grew its stake in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 3.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 40,208 shares of the biotechnology company’s stock after buying an additional 1,200 shares during the quarter. Dimensional Fund Advisors […] - 2025-05-14 04:32:47
- Blueprint Medicines Co. (NASDAQ:BPMC) Receives $126.56 Average Target Price from Analysts
- Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eighteen analysts that are currently covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation, thirteen have assigned a buy recommendation and one has given a strong buy recommendation to the company. […] - 2025-05-13 04:12:52
- CANADA LIFE ASSURANCE Co Has $541,000 Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)
- CANADA LIFE ASSURANCE Co lessened its stake in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 17.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,220 shares of the biotechnology company’s stock after selling 1,345 shares during the quarter. CANADA LIFE ASSURANCE Co’s holdings […] - 2025-04-30 05:48:53
- Needham & Company LLC Issues Pessimistic Forecast for Blueprint Medicines (NASDAQ:BPMC) Stock Price
- Blueprint Medicines (NASDAQ:BPMC – Get Free Report) had its price objective lowered by analysts at Needham & Company LLC from $133.00 to $130.00 in a report released on Monday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Needham & Company LLC’s target price would suggest a potential upside of 46.93% […] - 2025-04-30 02:46:52
- Wells Fargo & Company MN Cuts Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)
- Wells Fargo & Company MN reduced its position in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 38.9% in the fourth quarter, Holdings Channel.com reports. The fund owned 40,732 shares of the biotechnology company’s stock after selling 25,925 shares during the period. Wells Fargo & Company MN’s holdings in Blueprint Medicines were worth $3,553,000 as […] - 2025-04-23 05:06:57
- Barclays PLC Buys 17,931 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)
- Barclays PLC raised its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 10.5% during the 4th quarter, HoldingsChannel reports. The firm owned 189,127 shares of the biotechnology company’s stock after purchasing an additional 17,931 shares during the quarter. Barclays PLC’s holdings in Blueprint Medicines were worth $16,494,000 as of its most […] - 2025-04-21 04:56:54
- Blueprint Medicines Co. (NASDAQ:BPMC) Receives $124.95 Consensus Target Price from Analysts
- Shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the twenty-three analysts that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, fifteen have issued a buy recommendation and one […] - 2025-04-18 05:02:50
- Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by ExodusPoint Capital Management LP
- ExodusPoint Capital Management LP decreased its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 25.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,512 shares of the biotechnology company’s stock after selling 871 shares during the period. ExodusPoint Capital Management LP’s […] - 2025-04-14 04:46:56
- California Public Employees Retirement System Sells 24,735 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)
- California Public Employees Retirement System lowered its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 24.0% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 78,450 shares of the biotechnology company’s stock after selling 24,735 shares during the quarter. California Public Employees Retirement System’s holdings in Blueprint Medicines were worth […] - 2025-04-08 05:18:56
- Schroder Investment Management Group Sells 57,865 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)
- Schroder Investment Management Group lowered its stake in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 60.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 38,434 shares of the biotechnology company’s stock after selling 57,865 shares during the quarter. Schroder Investment Management […] - 2025-04-06 05:30:53
iShares US Equity Enhanced Active UCITS ETF USD (Acc) BPMC holdings
| Date | Number of BPMC Shares Held | Base Market Value of BPMC Shares | Local Market Value of BPMC Shares | Change in BPMC Shares Held | Change in BPMC Base Value | Current Price per BPMC Share Held | Previous Price per BPMC Share Held |
|---|
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of BPMC by Blackrock for IE0009VWHAE6
Show aggregate share trades of BPMC| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-07-09 | BUY | 55 | | | 128.550* | | 100.71 |
| 2025-07-07 | BUY | 25 | | | 128.400* | | 100.35 |
| 2025-07-03 | BUY | 60 | | | 128.350* | | 99.98 |
| 2025-07-01 | BUY | 2,400 | | | 128.340* | | 99.60 |
| 2025-06-18 | SELL | -70 | | | 128.120* | | 97.76  Profit of 6,843 on sale |
| 2025-06-16 | BUY | 110 | | | 128.250* | | 97.31 |
| 2025-06-13 | SELL | -14 | | | 127.960* | | 97.09 Profit of 1,359 on sale |
| 2025-06-09 | BUY | 180 | | | 127.970* | | 96.16 |
| 2025-06-05 | SELL | -15 | | | 127.900* | | 95.68 Profit of 1,435 on sale |
| 2025-05-28 | BUY | 60 | | | 95.300* | | 94.80 |
| 2025-05-14 | SELL | -416 | | | 97.510* | | 94.35 Profit of 39,248 on sale |
| 2025-05-12 | BUY | 12 | | | 100.310* | | 94.25 |
| 2025-05-07 | BUY | 30 | | | 99.800* | | 94.13 |
| 2025-05-01 | BUY | 36 | | | 99.250* | | 93.87 |
| 2025-04-29 | BUY | 458 | | | 88.480* | | 93.96 |
| 2025-04-16 | BUY | 156 | | | 82.110* | | 94.78 |
| 2025-04-15 | BUY | 624 | | | 81.450* | | 94.92 |
| 2025-04-14 | BUY | 102 | | | 82.530* | | 95.05 |
| 2025-04-11 | BUY | 180 | | | 80.840* | | 95.20 |
| 2025-04-10 | BUY | 210 | | | 80.270* | | 95.37 |
| 2025-04-08 | BUY | 114 | | | 79.220* | | 95.69 |
| 2025-04-07 | BUY | 258 | | | 80.200* | | 95.87 |
| 2025-04-02 | BUY | 48 | | | 90.010* | | 96.10 |
| 2025-04-01 | BUY | 462 | | | 85.940* | | 96.21 |
| 2025-03-31 | BUY | 60 | | | 88.510* | | 96.31 |
| 2025-03-28 | BUY | 630 | | | 88.720* | | 96.40 |
| 2025-03-26 | BUY | 840 | | | 90.720* | | 96.55 |
| 2025-03-25 | BUY | 90 | | | 93.080* | | 96.59 |
| 2025-03-21 | BUY | 72 | | | 88.720* | | 96.71 |
| 2025-03-14 | BUY | 18 | | | 89.580* | | 97.16 |
| 2025-03-11 | BUY | 6 | | | 87.761* | | 97.48 |
| 2025-03-05 | BUY | 12 | | | 89.921* | | 97.91 |
| 2025-02-21 | BUY | 6 | | | 92.250* | | 98.74 |
| 2025-02-11 | BUY | 292 | | | 101.570* | | 99.04 |
| 2025-01-21 | SELL | -572 | | | 111.959* | | 94.01 Profit of 53,772 on sale |
| 2025-01-17 | BUY | 592 | | | 110.050* | | 93.57 |
| 2025-01-15 | BUY | 8 | | | 104.890* | | 92.95 |
| 2025-01-08 | BUY | 8 | | | 90.631* | | 92.63 |
| 2024-11-22 | BUY | 168 | | | 94.151* | | 90.72 |
| 2024-11-19 | BUY | 8 | | | 94.600* | | 89.80 |
| 2024-11-01 | BUY | 26 | | | 90.698* | | 84.99 |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of BPMC
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-07-17 | 239,724 | 0 | 1,220,580 | 19.6% |
| 2025-07-16 | 757,379 | 0 | 2,715,041 | 27.9% |
| 2025-07-15 | 376,932 | 4 | 2,809,966 | 13.4% |
| 2025-07-14 | 981,796 | 0 | 3,991,208 | 24.6% |
| 2025-07-11 | 448,445 | 37 | 1,165,742 | 38.5% |
| 2025-07-10 | 184,340 | 367 | 1,150,146 | 16.0% |
| 2025-07-09 | 64,744 | 300 | 498,228 | 13.0% |
| 2025-07-08 | 76,815 | 83 | 796,214 | 9.6% |
| 2025-07-07 | 76,684 | 2,791 | 316,852 | 24.2% |
| 2025-07-03 | 138,599 | 1,282 | 301,123 | 46.0% |
| 2025-07-02 | 72,514 | 0 | 515,363 | 14.1% |
| 2025-07-01 | 96,425 | 60 | 828,685 | 11.6% |
| 2025-06-30 | 215,929 | 4 | 692,512 | 31.2% |
| 2025-06-27 | 111,993 | 0 | 637,035 | 17.6% |
| 2025-06-26 | 106,698 | 0 | 658,582 | 16.2% |
| 2025-06-25 | 118,444 | 0 | 607,276 | 19.5% |
| 2025-06-24 | 230,659 | 1,400 | 1,002,123 | 23.0% |
| 2025-06-23 | 112,133 | 9,752 | 708,232 | 15.8% |
| 2025-06-20 | 100,659 | 2 | 506,844 | 19.9% |
| 2025-06-18 | 115,124 | 0 | 824,113 | 14.0% |
| 2025-06-17 | 244,409 | 2 | 897,946 | 27.2% |
| 2025-06-16 | 160,251 | 713 | 798,678 | 20.1% |
| 2025-06-13 | 434,900 | 59 | 1,545,212 | 28.1% |
| 2025-06-12 | 397,343 | 253 | 741,973 | 53.6% |
| 2025-06-11 | 210,473 | 0 | 657,257 | 32.0% |
| 2025-06-10 | 115,812 | 0 | 615,758 | 18.8% |
| 2025-06-09 | 298,386 | 642 | 1,017,613 | 29.3% |
| 2025-06-06 | 97,748 | 0 | 558,191 | 17.5% |
| 2025-06-05 | 219,982 | 615 | 1,168,163 | 18.8% |
| 2025-06-04 | 372,324 | 19 | 1,053,140 | 35.4% |
| 2025-06-03 | 525,362 | 1,402 | 2,694,066 | 19.5% |
| 2025-06-02 | 3,965,557 | 7,858 | 15,312,845 | 25.9% |
| 2025-05-30 | 193,389 | 694 | 366,212 | 52.8% |
| 2025-05-29 | 311,140 | 83 | 710,746 | 43.8% |
| 2025-05-28 | 205,574 | 242 | 325,933 | 63.1% |
| 2025-05-27 | 162,236 | 630 | 320,788 | 50.6% |
| 2025-05-23 | 86,220 | 43 | 111,917 | 77.0% |
| 2025-05-22 | 113,092 | 1,417 | 187,169 | 60.4% |
| 2025-05-21 | 168,036 | 1,363 | 197,620 | 85.0% |
| 2025-05-20 | 94,343 | 528 | 152,007 | 62.1% |
| 2025-05-19 | 103,893 | 74 | 165,124 | 62.9% |
| 2025-05-16 | 118,285 | 836 | 194,440 | 60.8% |
| 2025-05-15 | 114,191 | 599 | 170,483 | 67.0% |
| 2025-05-14 | 83,285 | 104 | 127,090 | 65.5% |
| 2025-05-13 | 215,116 | 453 | 286,552 | 75.1% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Note: All information is provided as is without warranty and should be used for indicative purposes only.
You should independently check data before making any investment decision.
This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.
Copyright Market Footprint Ltd. Privacy Policy